Par’s initial shipments will comprise generically-labeled presentations of the Provigil product.
Modafinil, a wakefulness-prompting agent for oral administration, indicated to improve wakefulness in adult patients with excessive sleepiness related to narcolepsy, obstructive sleep apnea (OSA), and shift work disorder.
The product is indicated as an adjunct to standard treatment(s) for the underlying obstruction, in OSA.
Par acquired the US marketing rights to modafinil from Teva in connection with Teva’s acquisition of Cephalon in 2011.